As of 2026-10-02, the EV/EBITDA ratio of Novavax Inc (NVAX) is -28.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Novavax's latest enterprise value is 1,848.93 mil USD. Novavax's TTM EBITDA according to its financial statements is -65.83 mil USD. Dividing these 2 quantities gives us the above Novavax EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 15.8x | 14.9x |
| Forward P/E multiples | 14.1x - 16.4x | 15.0x |
| Fair Price | (5.69) - 12.91 | 2.56 |
| Upside | -153.7% - 21.8% | -75.9% |
| Date | EV/EBITDA |
| 2026-09-30 | -28.36 |
| 2026-09-29 | -28.64 |
| 2026-09-28 | -28.59 |
| 2026-09-25 | -28.16 |
| 2026-09-24 | -28.09 |
| 2026-09-23 | -27.96 |
| 2026-09-22 | -28.66 |
| 2026-09-21 | -27.61 |
| 2026-09-18 | -26.86 |
| 2026-09-17 | -26.59 |
| 2026-09-16 | -24.96 |
| 2026-09-15 | -24.66 |
| 2026-09-14 | -25.56 |
| 2026-09-11 | -25.14 |
| 2026-09-10 | -24.84 |
| 2026-09-09 | -26.21 |
| 2026-09-08 | -27.06 |
| 2026-09-04 | -27.14 |
| 2026-09-03 | -27.44 |
| 2026-09-02 | -27.39 |
| 2026-09-01 | -26.89 |
| 2026-08-31 | -25.01 |
| 2026-08-28 | -24.74 |
| 2026-08-27 | -24.21 |
| 2026-08-26 | -24.61 |
| 2026-08-25 | -25.19 |
| 2026-08-24 | -23.74 |
| 2026-08-21 | -23.94 |
| 2026-08-20 | -22.64 |
| 2026-08-19 | -23.56 |
| 2026-08-18 | -21.42 |
| 2026-08-17 | -21.77 |
| 2026-08-14 | -21.72 |
| 2026-08-13 | -21.94 |
| 2026-08-12 | -21.49 |
| 2026-08-11 | -21.47 |
| 2026-08-10 | -21.32 |
| 2026-08-07 | -21.47 |
| 2026-08-06 | -20.94 |
| 2026-08-05 | -20.84 |
| 2026-08-04 | -20.74 |
| 2026-08-03 | -20.12 |
| 2026-07-31 | -19.89 |
| 2026-07-30 | -20.19 |
| 2026-07-29 | -19.94 |
| 2026-07-28 | -20.02 |
| 2026-07-27 | -20.32 |
| 2026-07-24 | -20.24 |
| 2026-07-23 | -21.15 |
| 2026-07-22 | -21.37 |